SCHEMBL3946692

SCHEMBL3946692

CC(C)c1ccccc1-c1cc(Cl)nc(N)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 10/20 0.64
▸ HSP90AB1 P08238 9/20 0.64
▸ KDM4E B2RXH2 1/20 0.54
▸ DHFR P00374 1/20 0.47
▸ CDC7 O00311 1/20 0.44
▸ DAPK3 O43293 1/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ PAK4 O96013 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ PRKACA P17612 1/20 0.44
▸ GRK5 P34947 1/20 0.44
▸ MAP2K2 P36507 1/20 0.44
▸ MAPK8 P45983 1/20 0.44
▸ CSNK1A1 P48729 1/20 0.44
▸ CDK8 P49336 1/20 0.44
▸ CLK2 P49760 1/20 0.44
▸ GSK3A P49840 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ CDK7 P50613 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566525 1.00 HSP90AA1 (0.64) HSP90AA1HSP90AB1KDM4EDHFRCDC7
SCHEMBL29567149 0.98 HSP90AA1 (0.62) HSP90AA1HSP90AB1KDM4EDHFRCDC7
SCHEMBL24309341 0.79 DHFR (0.45) HSP90AA1HSP90AB1DHFRHTR1BHTR2B
SCHEMBL29567313 0.79 DHFR (0.45) HSP90AA1HSP90AB1DHFRHTR1BHTR2B
SCHEMBL29600361 0.79 HSP90AA1 (0.55) HSP90AA1HSP90AB1KDM4EDHFRADCY10
SCHEMBL24323700 0.79 HSP90AA1 (0.55) HSP90AA1HSP90AB1KDM4EDHFRADCY10
SCHEMBL29571104 0.79 HSP90AA1 (0.70) HSP90AA1HSP90AB1KDM4EDHFRCDC7
SCHEMBL3952089 0.79 HSP90AA1 (0.70) HSP90AA1HSP90AB1KDM4EDHFRCDC7
SCHEMBL3950560 0.78 HSP90AA1 (1.00) HSP90AA1HSP90AB1KDM4ECDC7DAPK3
SCHEMBL24310645 0.77 DHFR (0.43) HSP90AA1HSP90AB1DHFRHTR1BHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 — — US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 — — US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 — — US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 — — EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HSP90AA1 1490/4885HSP90AB1 998/4885KDM4E 4141/4885
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885KDM4E 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback